Blood Res.  2016 Dec;51(4):220-222. 10.5045/br.2016.51.4.220.

Salvage treatment of relapsed/refractory LCH

• Seo JJ

• KMID: 2364309
• DOI: http://doi.org/10.5045/br.2016.51.4.220

Abstract

No abstract available.

MeSH Terms

Salvage Therapy*

Reference

1. Rigaud C, Barkaoui MA, Thomas C, et al. Langerhans cell histiocytosis: therapeutic strategy and outcome in a 30-year nationwide cohort of 1478 patients under 18 years of age. Br J Haematol. 2016; 174:887–898. PMID: 27273725.

2. Donadieu J, Bernard F, van Noesel M, et al. Cladribine and cytarabine in refractory multisystem Langerhans cell histiocytosis: results of an international phase 2 study. Blood. 2015; 126:1415–1423. PMID: 26194764.

3. Simko SJ, Tran HD, Jones J, et al. Clofarabine salvage therapy in refractory multifocal histiocytic disorders, including Langerhans cell histiocytosis, juvenile xanthogranuloma and Rosai-Dorfman disease. Pediatr Blood Cancer. 2014; 61:479–487. PMID: 24106153.

4. Monsereenusorn C, Rodriguez-Galindo C. Clinical Characteristics and treatment of Langerhans cell histiocytosis. Hematol Oncol Clin North Am. 2015; 29:853–873. PMID: 26461147.

5. Allen CE, Ladisch S, McClain KL. How I treat Langerhans cell histiocytosis. Blood. 2015; 126:26–35. PMID: 25827831.

6. Veys PA, Nanduri V, Baker KS, et al. Haematopoietic stem cell transplantation for refractory Langerhans cell histiocytosis: outcome by intensity of conditioning. Br J Haematol. 2015; 169:711–718. PMID: 25817915.

7. Uppuluri R, Ramachandrakurup S, Subburaj D, Bakane A, Raj R. Excellent remission rates with limited toxicity in relapsed/refractory Langerhans cell histiocytosis with pulse dexamethasone and lenalidomide in children. Pediatr Blood Cancer. 2017; 64:110–112. PMID: 27555565.

8. Haroche J, Cohen-Aubart F, Emile JF, et al. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood. 2013; 121:1495–1500. PMID: 23258922.

9. Aricò M. Langerhans cell histiocytosis in children: from the bench to bedside for an updated therapy. Br J Haematol. 2016; 173:663–670. PMID: 26913480.

10. Héritier S, Emile JF, Barkaoui MA, et al. BRAF mutation correlates with high-risk Langerhans cell histiocytosis and increased resistance to first-line therapy. J Clin Oncol. 2016; 34:3023–3030. PMID: 27382093.